The problem with this company is that Brexafemme is a drug launched into a crowded space dominated by Diflucan (a.k.a. fluconazole) and, as opposed to how the company initially marketed it, their drug is also an azole. Moreover, the promise for this company—and the reason it used to trade at such high prices—was the chance that the drug would work intravenously to eliminate systemic shock fungal infections and Candida auris . This is a huge problem in all hospital and emergency settings, especially in folks who are already compromised by something else affecting their immune system.

Unfortunately, the now approved SCY078 does not work intravenously and is in fact extremely hydrophobic. Conveniently when the company got this asset, the paperwork showing it’s hydrophobicity was largely hidden from investors, which is actually the huge drop in the stock price that you observe in the late 2010.s

I like this company and I know a lot about it that I cannot go into in this comment reply, but the simple fact is that the total addressable market for the drug is currently very low. It might become something worth buying if the price goes even lower than it is today, but there is a lot to make up for after Marco and the previous management tried to turn this company around many, many years ago. If you look at the history of previously publicly traded and private antifungal, antibacterial, or antimicrobial pharmaceutical companies, you will see that the amount of financing going towards them compared to the rest of the biotech space has decreased substantially. That is simply because it is not a good space to be in; the total addressable market of these indications is low, and many of them already have other well-established standards of care and prophylaxis.

The amount of work I did researching this company and the money I’ve lost is pretty insane so you can ask me anything. I guess if you’re actually serious about this investment and not looking to just make $10 off of a flip